Compare LTRX & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LTRX | IMUX |
|---|---|---|
| Founded | 1989 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.5M | 85.8M |
| IPO Year | 2000 | N/A |
| Metric | LTRX | IMUX |
|---|---|---|
| Price | $5.64 | $0.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $6.17 | $6.00 |
| AVG Volume (30 Days) | 463.3K | ★ 1.4M |
| Earning Date | 02-05-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $118,294,000.00 | N/A |
| Revenue This Year | $4.59 | N/A |
| Revenue Next Year | $12.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.91 | $0.55 |
| 52 Week High | $6.75 | $1.39 |
| Indicator | LTRX | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 55.17 | 35.53 |
| Support Level | $5.54 | $0.55 |
| Resistance Level | $5.93 | $0.65 |
| Average True Range (ATR) | 0.38 | 0.04 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 43.49 | 14.66 |
Lantronix Inc is a networking company. It provides secure data access and management solutions for the Internet of Things (IoT) and information technology assets. It organizes its products and solutions into three product lines: Embedded IoT Solutions, IoT Systems Solutions, and Software and Services. The IoT System Solutions segment is the key revenue driver for the company. The company serves a diverse range of markets including healthcare, industrial, security, energy, transportation, and government networking. Its primary geographic markets are the Americas, Europe, the Middle East and Africa, and Asia Pacific Japan. The Americas contribute the vast majority of total revenue.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.